Premium
Epstein–Barr virus (EBV) deletions as biomarkers of response to treatment of chronic active EBV
Author(s) -
Venturini Cristina,
Houldcroft Charlotte J.,
Lazareva Arina,
Wegner Fanny,
Morfopoulou Sofia,
Amrolia Persis J.,
Golwala Zainab,
Rao Anupama,
Marks Stephen D.,
Simmonds Jacob,
Yoshikawa Tetsushi,
Farrell Paul J.,
Cohen Jeffrey I.,
Worth Austen J.,
Breuer Judith
Publication year - 2021
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/bjh.17790
Subject(s) - virus , biology , immunology , saliva , epstein–barr virus , virology , disease , medicine , biochemistry
Summary Chronic active Epstein–Barr virus (CAEBV) disease is a rare condition characterised by persistent EBV infection in previously healthy individuals. Defective EBV genomes were found in East Asian patients with CAEBV. In the present study, we sequenced 14 blood EBV samples from three UK patients with CAEBV, comparing the results with saliva CAEBV samples and other conditions. We observed EBV deletions in blood, some of which may disrupt viral replication, but not saliva in CAEBV. Deletions were lost overtime after successful treatment. These findings are compatible with CAEBV being associated with the evolution and persistence of EBV + haematological clones that are lost on successful treatment.